# XTX301 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05684965/  
OnCo record `nct05684965` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of XTX301 in advanced solid tumours, run by Xilio Development, Inc., now recruiting.

## Summary

XTX301 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05684965 by Xilio Development, Inc., with 358 participants planned, started 2023-05-11 and due to reach its primary completion in 2028-09. Interventions recorded: XTX301.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05684965
- Phase: 1/2
- Setting: A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors
- Sponsor: Xilio Development, Inc.
- Enrolled: 358

## Sources

- ClinicalTrials.gov NCT05684965: https://clinicaltrials.gov/study/NCT05684965

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Xilio Therapeutics](https://onco.cc/companies/xilio-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05684965.json